UFMS Approach to Nitrosamine Analysis

Nitrosamine compounds are classified as probable human carcinogens. Ever since the first FDA notification in June 2018 about levels of these impurities in pharmaceutical API, the number of recalls have been on a rise for  angiotensin II receptor blockers and other products like Ranitidine, Metformin etc. The FDA and the European Medicine Agency (EMA) have constantly set and update the guidelines in measuring impurities in pharmaceutical products. 

Holistic solution to measurement of nitrosamines needs both GC-MS/MS and LC-MS/MS technologies. Download the handbook to find out more about qualitative and quantitative analysis of these compounds. 

Product Overview